T
OTALLY implantable drug infusion systems and neurosurgical catheter placement methods render it possible to overcome long-standing problems of drug delivery to the brain. ~4 Direct infusion of drugs into the cerebrospinal fluid (CSF) obviates the problems of systemic drug side effects, peripheral drug inactivation, poor drug absorption, serum protein binding, blood-brain barrier penetration, and poor patient compliance. ~4 Based on extensive data implicating a deficit in brain cholinergic activity in patients with Alzheimer's disease,~ a feasibility trial of intracerebroventricular (ICV) infusion of a muscarinic agonist, bethanechol chloride, was carried out. ~5 The results of this trial demonstrated the feasibility of the drug delivery technique but did not document objective improvement in cognitive function.~4-~ Therefore, a collaborative placebo-controlled double-blind crossover study was designed to further evaluate ICV bethanechol chloride infusion in patients with biopsy-documented Alzheimer's disease.*
Clinical Material and Methods

Patient Selection
Patients were recruited for the study from January, 1985, until April, 1986. All patients selected for the study met the criteria of the National Institute of Neurological Disorders and Stroke Alzheimer's Disease and Related Disorders Association for the clinical diagnosis of probable Alzheimer's disease. 2~ In addition, all patients had to meet the following selection criteria: t) Global Deterioration Scale 23 scores of 4 or 5; 2) MiniMental State ~~ score between 9 and 25; 3) Hamilton * Institutions, personnel, and funding agencies involved in this study are listed in the Appendix.
Depression Scale ~2 score of less than 9; 4) Hachinski Ischemia Scale ~' score of less than 5; 5) live with a responsible adult willing and able to cooperate with the requirements of the study; and 6) written informed consent from the patient and the next of kin. Patients were excluded t?om the study if they failed to meet all of these criteria, had evidence of a seizure disorder or an epileptogenic focus on electroencephalography, had any evidence of coagulopathy or required active anticoagulation therapy, had other debilitating or lifethreatening diseases, or demonstrated a hypersensitivity reaction to a 2.5-rag subcutaneous test dose of bethanechol chloride.
Surgical Procedure and Infusion System
The surgical procedure of placement and the mechanism of the Infusaid pump? have been reported previously. ~3-j5 Briefly, a right frontal cortical biopsy was performed and a Silastic catheter was passed transcortically into the fight lateral ventricle. Intracerebroventricular placement was documented by free flow of CSF from the catheter. An Infusaid pump was implanted subcutaneously on the abdomen or chest, and the pump outflow catheter was tunneled subcutaneously and attached to the intraventricular catheter.
Study Design
After meeting all criteria for acceptance into the study, patients were given a baseline neuropsychological test battery to assess a broad range of cognitive functions known to be adversely affected in Alzheimer's disease patients. The baseline test battery consisted of the following items: 1) Digit Symbol, Block Design, and Digit Span subtests of the Wechsler Adult Intelligence Scale; 29 2) Russell re~ision of the Wechsler Memory Scale; 26 3) Trails A and B; 24 4) Buschke-Fuld Selective Reminding Task; 6 5) Word Fluency; 27 6) Boston Naming; 16 and 7) Mini-Mental State. ~o A fight frontal cortical brain biopsy '3 and implantation of the infusion system ~5 were then carried out under general anesthesia. Biopsy tissue was used to document the light and electron microscopic changes consistent with Alzheimer's disease and for other studies. Histological diagnosis of Alzheimer's disease was made at each institution by a neuropathologist who was not directly involved with the study. In addition, tissue from most centers was sent to William R. Markesbery, M.D., at the University of Kentucky Medical Center for review and confirmation of the histological diagnosis.
After brain biopsy and implantation of the infusion system, all patients received 6 weeks of saline placebo infusion, after which the baseline neuropsychological test battery was repeated. Patients were then randomly assigned in a double-blind fashion to one of two schedules of drug/placebo infusion. Patients entered in ~ Infusaid pump manufactured by Shiley Infusaid, Inc., Norwood, Massachusetts.
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Schedule A received 12 weeks of drug infusion followed by 12 weeks of placebo infusion. Patients entered in Schedule B received 12 weeks of placebo infusion followed by 12 weeks of drug infusion. Drug and placebo solutions were prepared at each center in identical bottles for each patient. Infusion pumps were refilled at 3-week intervals throughout the study period. Data were kept at each institution and copies were sent to the coordinating center (the Dartmouth-Hitchcock Medical Center) for analysis. No person having any contact with the patients was allowed access to the randomization code until all patients had finished the study. Patients and families were not informed of the single crossover design of the randomization schedule.
The baseline neuropsychological test battery described above was administered four times: preoperatively, at the time of randomization, at the time of crossover, and at the end of the study. A shorter neuropsychological test battery, composed of Items 4 through 7 of the baseline test battery, was administered 3, 9, 12, 15, 21, 24, and 27 weeks after surgery.
Drug Selection and Dose
Bethanechol chloride, a pure muscarinic agonist that is highly water-soluble, not degraded by cholinesterases, and stable in solution, was chosen for infusion? 5 Bethanechol chloride solution was prepared at a concentration of 0.2 mg/ml. Infusion pump flow rates ranged between 1 and 2 ml/day; therefore, the daily drug dose for patients in this study ranged from 0.2 to 0.4 rag/ day. No attempts were made to perform a dose-finding phase before the patients were entered in the doubleblind phase of the study. However, data from previous patients suggested that this dose range was well tolerated and, by family reports, had produced recognizable behavioral improvement. ~~
Statistical Analysis
A preliminary analysis was performed to compare each of the two treatment groups (A and B) using multivariate analysis of variance for repeated measures. The two groups did not differ significantly with respect to any baseline measure such as age, duration of illness, or severity of cognitive dysfunction at the time of entry into the study.
Both parametric (repeated measures analysis of variance) and nonparametric (Wilcoxon matched-pairs signed-rank test 7) analyses were used to examine differences between test measures under placebo and drug conditions. Both analyses revealed the same statistically significant measures. Because of our concern about achieving statistical significance only because of the number of outcome measures used, a stringent p value of 0.02 was required for significance.
Results
Patient Profile
Sixty-eight patients were entered in the study and underwent biopsy and infusion system placement. At the time of data analysis, eight patients did not meet all inclusion criteria; eight patients did not have biopsy confirmation of Alzheimer's disease (six nondiagnostic biopsies and two patients with Pick's disease); two patients could not complete the study because of complications; and a protocol violation was found for one patient. All of these patients were deleted from the data analysis. The data for the 49 remaining patients are summarized in Table 1 .
Neuropsychological Test Scores
Wilcoxon matched-pairs signed-rank test 7 analyses of neuropsychological test scores are summarized in Table 2 . Only the Mini-Mental State ~~ examination showed statistically significant improvement with drug infusion, and the degree of improvement was quite modest. On Trails A testing, 24 performance was significantly worse during periods of drug infusion. No other statistically significant changes were noted. 
Complications
Sixty-eight patients underwent pump implantation and biopsy. The related complications are summarized in Tables 3 and 4 . One patient developed pneumonia postoperatively and died, and one patient suffered a persistent, focal neurological deficit from hemorrhage at the surgical site. No other irreversible complications were encountered. Thirteen of the 20 total complications (one postoperative death, two hemorrhages, seven patients with seizures, and three infections) were directly related to the surgical procedure. Three complications, all reversible, were related to the infusion system; four reversible complications were drug-related.
Discussion
The cholinergic hypothesis of Alzheimer's disease has been extensively reviewed ~,s and will not be discussed here. Despite numerous data suggesting that a loss of brain cholinergic function may be causally related to at least some of the symptoms of patients with Alzheimer's disease, attempts to increase cholinergic activity have met with, at best, marginal success? Even if the cholinergic hypothesis is correct, problems with pres- ently available drugs and drug delivery to the brain may limit the efficacy of cholinergic therapy for patients with Alzheimer's disease. 2'~4 By delivering a drug directly into the CSF one may overcome many problems involved with drug delivery to the brain and be able to evaluate potentially therapeutic compounds, which otherwise would not be clinically applicable. ~4 Therefore, after toxicity testing in animals, a feasibility trial of ICV infusion of a cholinergic agonist was carried out ~5 and the present study was designed. This study further documents the feasibility of ICV drug infusion for patients with Alzheimer's disease. In addition, ICV infusion of a cholinomimetic drug, bethanechol chloride, produced a statistically significant (but clinically irrelevant) improvement in Mini-Mental State ~~ test scores in this group of patients with biopsydocumented Alzheimer's disease. On Trails A testing, 24 performance was significantly worse during drug infusion. This may be due to generalized motor slowing secondary to cholinergic drug infusion. In three patients this effect was quite marked, producing clinically significant bradykinesia and rigidity requiring L-dopa therapy. Other neuropsychological outcome measures were not significantly affected. The magnitude of improvement in Mini-Mental State test scores and the lack of improvement in other measures lead us to conclude that treating more patients with bethanechol chloride is not justifiable.
The essentially negative results of this study can be explained by one or more of the following: I) inappropriate drug selection or dose; 2) inappropriate patient selection or selection of outcome measures; 3) inadequacy of the cholinergic hypothesis of Alzheimer's disease; or 4) inadequacy of drug delivery. Bethanechol chloride, a pure muscarinic agonist with greater M2 than M~ receptor affinity, is not the theoretically ideal drug for cholinergic replacement therapy in Alzheimer's disease, z'~9 However, at present, it is the only clinically available muscarinic agonist appropriate for ICV infusion.J4 Therefore, lack of response may be due solely to use of an inappropriate compound.
It is also possible that dose-response studies in each patient prior to institution of the double-blind trial would have produced a more robust response to drug infusion. Some modest dose-response effects have been seen with ICV bethanechol chloride infusion in patients with Alzheimer's disease; 2~ however, dose variation outside the range used in this study has not demonstrated any dramatic clinical improvement. We think it is safe to say that ICV bethanechol chloride will not be clinically effective in Alzheimer's disease.
Inappropriate patient selection is an unlikely reason for failure. Not only did these patients meet rigid clinical criteria for a diagnosis of Alzheimer's disease, 2~ but biopsy confirmation was obtained in all patients used for data analysis. Treatment of less compromised patients might improve response to drug therapy, but an unequivocal clinical diagnosis of Alzheimer's disease would be very difficult to make in such patients. 2~
The neuropsychological test battery chosen for this study may be insensitive to drug effects. However, the battery was designed to evaluate a broad range of neuropsychological functions, including memory, language, orientation to surroundings, and attention, which are known to be affected in patients with Alzheimer's disease. Any clinically meaningful improvement in cognitive function would probably be measured by the test battery used in this study.
Inadequacy of the cholinergic hypothesis is a possible reason for failure to show a clinically meaningful response to drug infusion. Numerous attempts at cholinergic replacement therapy have met with, at best, marginal success? Only one controversial report has demonstrated a marked clinical response to cholinergic therapy in a reportedly double-blind study. 28 Although more receptor-specific drugs may improve the response to therapy, 2'19 at present the preponderance of the available data suggests that cholinergic replacement therapy is not an effective strategy for the treatment of patients with Alzheimer's disease. 2"5
Finally, the adequacy of drug delivery can be questioned. Although there are reliable data available demonstrating penetration of appropriate compounds from the CSF into the brain, 3' 4' 18' 22' 25 the distribution of bethanechol chloride after ICV infusion is unknown. In addition, diffuse activation of M I and M2 muscarinic receptors may not mimic the effects of anatomically specific, intermittent muscarinic receptor activation.
Although the positive cognitive effects in this study were minimal, the drug delivery system and chronic ICV drug infusion were generally well tolerated. Surgical complications were most likely associated with the cortical biopsy. The incidence and types of complications noted are similar to those published in other biopsy series. 9~t7 We suspect that morbidity from infusion system placement without biopsy would be extremely low. As with many surgical procedures, increasing experience appears to result in decreasing complications. In this study, two centers accounted for 41% of the patients enrolled but only 17% of the surgically related complications (seizures, hemorrhage, infection). For these two centers, the complication rate was 7%, with none of the complications being irreversible. The Infusaid pumps have been very reliable, with only one pump failure during the study. Patients involved in earlier studies have continued to demonstrate reliable pump function for nearly 5 yearsJ 5
Our study demonstrates a lack of efficacy of ICV bethanechol chloride infusion in the treatment of Alzheimer's disease. However, the clinical application of this method of drug deliver3, is still potentially valuable. Intracerebroventricular infusion may allow clinical use of otherwise clinically inapplicable drugs such as possibly therapeutic compounds that are rapidly metabolized systemically, have unacceptable peripheral side effects at systemic doses, and/or do not cross the blood-brain barrier. 14 With adequate preclinical toxicity screening and meticulous neurosurgical technique, BethanechoI chloride for Alzheimer's disease implantabte drug infusion systems for intracranial drug infusion can be used safely and may find a place in the treatment of neurological disease.
